Fig. 3

Development of novel, flow cytometry-based assays for CNS-specific and AD-associated markers on plasma EVs a example histograms showing populations of EVs which were positive for each marker after labeling with fluorophore-conjugated antibody; plasma EVs labeled using fluorophore-conjugated immunoglobulin G isotype control for the indicated marker target antibody; and plasma EVs incubated with dye (fluorophore only, no antibody) control experiment. b Histogram of remaining particles after depletion of EVs from plasma by ultracentrifugation. c Histogram of PBS incubated with fluorophore-conjugated antibody. d–f Summary data from experiments demonstrating specificity of EVs assays (n = 3) (d), linearity in different dilutions of EVs plasma samples (n = 3) (e), and stability of reference plasma (two replicates run each day on 5 separate days of the experiment) for GABRD, GPR162 and pTau217 (f). Positive particles were circled out using red boxes